Weiss jemand warum der Kurs vom Flamel (FLML) so schwach ist? - 500 Beiträge pro Seite

[koalabaer25]

Hallo,

wenn das so weitergeht, dann ist Flamel bald ein Pennystock. Sollte man kaufen oder noch warten? Meinungen sind erwünscht!

Grüsse
Koalabaer25

[puhvogel]

Die Kapitalreserven sind ziemlich schwach.
Weswegen hast Du die gekauft?

[koalabaer25]

Hi puhvogel,

Danke für die Antwort. Zum einen wurde Flamel u.a. vom Value Investor u. Sturza (?) empfohlen. Die Analyse hat mir gefallen. Flamel soll ab 2001 Gewinne schreiben. Zum anderen sind die Instis mit 41%! in dem Wert vertreten (siehe unter www.lionshares.com). Mehr kann ich nicht dazu sagen und hoffe auf steigende Kurse.

Gruß
Koalabaer25

[kunigund]

Bei Flamel gibts wohl Verzögerungen bei Basulin. Ausserdem ist bzgl Kooperationen noch nicht viel vermeldet worden.

Sturza hat sich inzwischen ziemlich negativ geäussert und wird wohl die Empehlung zurückziehen, wenn sich nicht bald was tut

[Chalifmann]

Hi, Flamel in neuster Ausgabe von `Börse-Online` zum Thema
Nanotechnologie als "hochriskante Aktie" erwähnt :

-Ziel soll sein, die Wirkstoffdosierung von Medikamenten im Körper durch
Proteine, eingebettet in Nanokapseln aus Polyaminosäuren, zu optimieren.

-Ich habe mal in die Pipeline geschaut, und offenbar
wird mit dieser Technologie (Medusa), zusammen mit Novo Nordisk
an Diabetes - Typ 1 und Typ 2 gearbeitet ... in Phase 1.

-Die Company hat aber auch schon ein Schmerzmittel am Markt
und eines gegen Herpes der BLA Prüfung, über die Kapitalreserven habe ich
jedoch unterschiedliche Angaben, z.b. bei Yahoo ist der `Total Cash` mit 0,nix beziffert,
andere Quellen geben `current assets` zwischen 10 und 15 millionen dollar an.

Hm ... ?

[Chalifmann]

Ob das Potential der aktie mit der von Amylin
vergleichbar ist, wenn das klappt mit Basulin ?

[Chalifmann3]

Kein Interesse mehr hier, Flamel ist immerhin etliche hundert % gestiegen ...

[Chalifmann3]

Human Studies show Flamel Technologies` Medusa Protein Delivery System BASULIN Challenges Lantus for the 24-hour Controlled Release of Insulin

Monday March 24, 9:29 am ET

LYON, France--(BUSINESS WIRE)--March 24, 2003--Flamel Technologies S.A. (NASDAQ:FLML - News) announced today that the results of its second human clinical trial on BASULIN® have been completed, with excellent results.
The trial, which was conducted on 16 healthy volunteers using the clamp technique, showed that BASULIN provided a similar pharmacokinetic profile to the Aventis product, Lantus®, with at least the same efficacy.

Dr Gerard Soula, president and ceo of Flamel explained: "Our first clinical trial proved the concept of our controlled-release, 24-hour insulin against the Novo Nordisk product, NPH. This new study was designed to compare our optimized formulation of BASULIN with Lantus, a recently introduced product which is increasingly recognized as the best long-acting product to treat Type I and Type II diabetes." The study was designed to measure the efficacy of BASULIN versus Lantus by infusing glucose over a twenty-four hour period in order to compensate for the hypoglycemic effect of the insulin release by the two formulations.

Dr. Soula continued: "We are very excited by the results which show that BASULIN released insulin during a twenty-four hour period at a constant rate with good bioavailability and excellent local tolerance. I believe that this is a key technical and clinical milestone for the development of BASULIN."

"Among BASULIN`s many advantages," continued Dr. Soula, "the most important is that BASULIN is a controlled release of human insulin, not an artificial insulin like Lantus. It is recognized that the most significant breakthough for insulin therapy has been the use of human insulin, instead of bovine or porcine insulin, which are different by one or two amino acids in the sequence of the protein. Flamel`s goal with BASULIN is to deliver human insulin in order to reduce the risk of potential immune response which can be created by non-human insulin, such as artificial or animal insulins. I believe controlled-release human insulin products are what physicians and patients have been seeking for decades."

Flamel is preparing a Phase II-a study of Basulin, while actively negotiating with a number of major biopharmaceutical companies for the licensing of this product.

Dr. Soula also announced that: "Flamel intends also to do a human clinical study with its Medusa® formulation of interferon alpha, versus pegylated interferon. We expect these studies will show the potential of our Medusa technology."

Na, also !

[francoir]

GlaxoSmithKline and Flamel Technologies Announce License

Agreement

LONDON and LYON, France, March 28 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK; London) and Flamel Technologies S.A. (Nasdaq: FLML) announced today that they have entered into an agreement whereby Flamel has licensed its controlled-release Micropump(R) technology to GlaxoSmithKline ("GSK") to develop a new formulation for an undisclosed existing product. Flamel will receive an upfront payment of $2M and additional milestone payments upon achievement of certain events, and royalties on sales of the product. Based on the continued successful development and commercialisation of this formulation, GSK and Flamel estimate payments to Flamel could range up to $45 million by the end of the first year following launch, of which $25M is attributable to the product reaching certain milestones. Flamel may also participate in the manufacture of product. Additional terms of the agreement have not been disclosed.

Gerard Soula, PhD., president and chief executive officer of Flamel, said, "We are very excited about this new development agreement with GSK. We are confident of the potential of Micropump technology for these large, and still growing, markets. This additional agreement further demonstrates the interest of major worldwide pharmaceutical companies in our versatile technology platforms. Moreover, this is our second license agreement with GSK within the past nine months, based on Micropump technology. It confirms the common interest of the two companies to work together. I am very pleased and proud to see GSK, one of the world`s premier pharmaceutical companies, expand its relationship with Flamel."

Lawson Macartney, DVM., PhD., FRCPath, Head of the Cardiovascular, Metabolic and Urology Therapeutic Areas, GSK, added, "This collaboration will help us to maintain our leadership in product research and development. We are eager to develop with Flamel, leading technologies within our therapeutic areas with the objective of providing the next generation of medicines."

GlaxoSmithKline -- one of the world`s leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Flamel`s Micropump(R) technology is a controlled release and taste-masking technology for the oral administration of small molecule drugs. Flamel`s Medusa(R) nano-particulate technology is designed to deliver therapeutic proteins. Flamel`s expertise in polymer science has also been instrumental in the development of a photochromic eyeglass lens product now marketed by Corning Inc.

This document contains a number of matters, particularly as related to the status of various research projects and technology platforms, that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The presentation reflects the current view of management with respect to future events and is subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development, the impact of competitive products and pricing, and the risks associated with Flamel`s reliance on outside parties and key strategic alliances. These and other risks are described more fully in Flamel`s Annual Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 2000. Flamel assumes no obligation to update any forward-looking statements.

SOURCE GlaxoSmithKline

-0- 03/28/2003

/CONTACT: US Media inquiries: Nancy Pekarek, [phone], or Mary Anne Rhyne, [phone], or Patty Seif, [phone], or UK Media inquiries: Martin Sutton, [phone], or Siobhan Lavelle, [phone], or David Mawdsley, [phone], or US Analyst & Investor inquiries: Frank Murdolo, [phone], or Tom Curry, [phone], or European Analyst & Investor inquiries: Duncan Learmouth, [phone], or Anita Kidgell, [phone], or Philip Thomson, [phone], all of GlaxoSmithKline; or Dr. Gerard Soula, C.E.O., (33) 4-72-78-34-34, Fax: [phone] or [e-mail]; or Stephen H. Willard, C.F.O., [phone], Fax: [phone] or [e-mail], both of Flamel/

/Company News On-Call: http://www.prnewswire.com/gh/cnoc/comp/801350.html/

/Web site: http://www.gsk.com /

(GSK FLML)

CO: GlaxoSmithKline; Flamel Technologies S.A. ST: Pennsylvania, France, England IN: MTC HEA BIO SU: LIC

Jepp!